Merck & Company, Inc.
Recent
price
P/E
ratio
div
yld
2.27%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Company News
Merck & Co., Inc. $MRK Stock Position Increased by Fifth Third Wealth Advisors LLC
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Merck & Co., Inc. $MRK Stock Position Increased by Brookstone Capital Management
Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Why Is Moderna Stock Sinking Thursday?
Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares
Merck & Co., Inc. $MRK Stock Holdings Lowered by Cantor Fitzgerald Investment Advisors L.P.
3,507 Merck & Co., Inc. $MRK Shares Bought by Cardinal Capital Management
27,739 Merck & Co., Inc. $MRK Shares Sold by Axxcess Wealth Management LLC
Merck & Co., Inc. $MRK Shares Purchased by Diversify Advisory Services LLC
Merck (MRK) Laps the Stock Market: Here's Why
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now
Merck (MRK) Stock Dips While Market Gains: Key Facts